Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17126987 | 0.93 | CA2 (0.40) | CA1CA2ALDH1A1POLB | |
| SCHEMBL24272781 | 0.85 | CA1 (0.47) | CA1CA2HPGDLMNATP53 | |
| SCHEMBL6906715 | 0.83 | CA1 (0.46) | CA1CA2HPGDLMNATP53 | |
| SCHEMBL29851517 | 0.83 | CA1 (0.46) | CA1CA2HPGDLMNATP53 | |
| SCHEMBL9192345 | 0.83 | CA1 (0.50) | CA1CA2HPGDLMNATP53 | |
| SCHEMBL20696115 | 0.83 | CA1 (0.46) | CA1CA2HPGDLMNATP53 | |
| SCHEMBL31072319 | 0.82 | CA1 (0.44) | CA1CA2HPGDLMNATP53 | |
| SCHEMBL17399584 | 0.81 | CA1 (0.43) | CA1CA2HPGDLMNATP53 | |
| SCHEMBL14570690 | 0.79 | ELANE (0.38) | CA2 | |
| SCHEMBL18951286 | 0.77 | CA2 (0.33) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3031817-B1 | TERPHENYL-2-OXY-PHOSPHITE AS LIGANDS IN HYDROFORMYLATION CATALYSTS | EVONIK DEGUSSA GMBH (DE) | 2019-05-01 | — | — | EP | disclosed |
| EP-3459960-A1 | BISPHOSPHITE LIGANDS WITH DIOXAPHOSPHEPIN BUILDING BLOCKS | Evonik Degussa GmbH (DE) | 2019-03-27 | — | — | EP | disclosed |
| EP-3459961-A1 | FOUR-TOOTHED PHOSPHINO PHOSPHITES | Evonik Degussa GmbH (DE) | 2019-03-27 | — | — | EP | disclosed |
| EP-3031815-B1 | TERPHENYL-2-OXY-PHOSPHITES AS LIGANDS IN HYDROFORMYLATION CATALYSTS | EVONIK DEGUSSA GMBH (DE) | 2019-02-20 | — | — | EP | disclosed |
| US-10011619-B2 | Process for reducing the chlorine content of organotetraphosphites | EVONIK DEGUSSA GMBH (DE) | 2018-07-03 | — | — | US | disclosed |
| EP-3029052-B1 | 9-Anthrol-monophosphit Esters as Ligands for Hydroformylation Catalysts | EVONIK DEGUSSA GMBH (DE) | 2018-02-28 | — | — | EP | disclosed |
| EP-3101022-B1 | MONOPHOSPHITES HAVING AN UNSYMMETRIC BIARYL UNIT | EVONIK DEGUSSA GMBH (DE) | 2018-02-28 | — | — | EP | disclosed |
| EP-3070093-B1 | NOVEL ORGANOPHOSPHORUS COMPOUNDS BASED ON ANTHRACENTRIOL | EVONIK DEGUSSA GMBH (DE) | 2018-02-07 | — | — | EP | disclosed |
| EP-3112373-B1 | NOVEL TETRADENTATE PHOSPHORUS LIGAND WITH HOSTANOX O3 GUIDE STRUCTURE | EVONIK DEGUSSA GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| US-9701697-B2 | Process for reducing the chlorine content of organotetraphosphites | EVONIK DEGUSSA GMBH (DE) | 2017-07-11 | — | — | US | disclosed |
| US-8003816-B2 | Bisphosphite ligands for hydroformylation catalyzed by transition metals | EVONIK OXENO GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003816-B2 | Bisphosphite ligands for hydroformylation catalyzed by transition metals | EVONIK OXENO GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| EP-2091958-B1 | BISPHOSPHITE LIGANDS FOR HYDROFORMYLATION CATALYZED BY TRANSITION METALS | EVONIK OXENO GMBH (DE) | 2011-04-27 | — | — | EP | disclosed |
| US-20100036143-A1 | BISPHOSPHITE LIGANDS FOR HYDROFORMYLATION CATALYZED BY TRANSITION METALS | EVONIK OXENO GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| US-20100036143-A1 | BISPHOSPHITE LIGANDS FOR HYDROFORMYLATION CATALYZED BY TRANSITION METALS | EVONIK OXENO GMBH (DE) | 2010-02-11 | — | — | US | disclosed |
| WO-2008071508-A1 | BISPHOSPHITE LIGANDS FOR HYDROFORMYLATION CATALYZED BY TRANSITION METALS | EVONIK OXENO GMBH (DE) | 2008-06-19 | — | — | WO | disclosed |
| US-6525143-B2 | Separation of catalyst by membrane filtration | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION | 2003-02-25 | — | — | US | disclosed |
| US-20020111438-A1 | Dendritic macromolecules for metal-ligand catalyzed processes | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC | 2002-08-15 | — | — | US | disclosed |
| WO-2002034389-A2 | DENDRITIC MACROMOLECULES FOR METAL-LIGAND CATALYZED PROCESSES | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2002-05-02 | — | — | WO | disclosed |
| US-6350819-B1 | SEPARATION OF THE DESIRED PRODUCT FROM THE CATALYST IS FACILITATED; HYDROFORMYLATION CATALYST; BRANCHES CONTAIN TERMINAL GROUPS DERIVED FROM ORGANOPHOSPHITES, ORGANOPHOSPHONITES AND/OR ORGANOPHOSPHINITES. | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100036143-A1 | BISPHOSPHITE LIGANDS FOR HYDROFORMYLATION CATALYZED BY TRANSITION METALS | SLC9B2, CTR9, POF1B | CA1 2038/4885CA2 429/4885HPGD 1390/4885 |
| US-10011619-B2 | Process for reducing the chlorine content of organotetraphosphites | DCPS, DDT, TET2 | CA1 665/4885CA2 356/4885HPGD 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.